Odetiglucan
- Generic Name
- Odetiglucan
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 53238-80-5
- Unique Ingredient Identifier
- Q6X9CNN54X
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT03555149
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Lawrence Feldman, MD
- Target Recruit Count
- 35
- Registration Number
- NCT03003468
- Locations
- 🇺🇸
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT02132403
- Locations
- 🇺🇸
UI Cancer Center, Chicago, Illinois, United States
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT02086175
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath